Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.
Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis.
Multiple sclerosis: potential risk factors in childhood and adolescence.
Alemtuzumab and Multiple Sclerosis: Another Note of Caution.
Charles bonnet syndrome after herpes simplex encephalitis.
Restriction genes for retroviruses influence the risk of multiple sclerosis.
Diaphragm Breathing Movement Measurement using Ultrasound and Radiographic Imaging: A Concurrent Validity.
Assessment of Autonomic Dysfunction in Childhood Guillain-Barré Syndrome.
Axonal excitability in X-linked dominant Charcot Marie Tooth disease.
Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia.
PI3Kγ inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice.
Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.
[Future issues of the multiple sclerosis treatment from a medical economic viewpoint].
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method.
Functional involvement of γ-secretase in signaling of the triggering receptor expressed on myeloid cells-2 (TREM2).
Microvesicles: What is the Role in Multiple Sclerosis?
[Collaborative networks between Spain and Latin America regarding multiple sclerosis].
Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus.
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].
A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
Erratum to: Reassessing the risk of natalizumab-associated PML.
Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis.
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Body Esteem Among Women with Multiple Sclerosis and its Relationship with Demographic, Clinical and Socio-Psychological Factors.

Pages